J&J: Quarterly adjusted EPS up 10.2%
(CercleFinance.com) - J&J announces Q2 sales of $22.
44bn, up 4.3% y-o-y.
The laboratory reports adjusted net earnings of $6.84bn, up 1.6%, and adjusted EPS of $2.82 (+10.2%).
The company also raises its operating sales forecast for 2024 to between $89.2bn and $89.6bn (vs. $88.7bn to $89.1bn previously), reflecting the acquisition of Shockwave Medical.
It has trimmed adjusted EPS forecasts for 2024: adjusted EPS is expected between $9.97 and $10.07 (vs. $10.57 and $10.72 previously), notably due to costs associated with recent strategic acquisitions.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
44bn, up 4.3% y-o-y.
The laboratory reports adjusted net earnings of $6.84bn, up 1.6%, and adjusted EPS of $2.82 (+10.2%).
The company also raises its operating sales forecast for 2024 to between $89.2bn and $89.6bn (vs. $88.7bn to $89.1bn previously), reflecting the acquisition of Shockwave Medical.
It has trimmed adjusted EPS forecasts for 2024: adjusted EPS is expected between $9.97 and $10.07 (vs. $10.57 and $10.72 previously), notably due to costs associated with recent strategic acquisitions.
Copyright (c) 2024 CercleFinance.com. All rights reserved.